FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949273846> ?p ?o ?g. }

• W2949273846 abstract "Background LAPIS-PsA is an ongoing, national, 52-week, multicenter, prospective, non-interventional study assessing long-term treatment with apremilast (APR) in adult patients with active psoriatic arthritis (PsA) in routine clinical practice in Germany. Objectives The current interim analysis assesses the clinical effectiveness of aPR, as measured with the Clinical Disease activity index for PsA (cDAPSA) and its core components, as well as PsA health-related quality of life (HRQoL), measured with the 9-domain PsA Impact of Disease Questionnaire (PsAID9). In addition, correlations between cDAPSA and PsAID9 were assessed. Methods The interim analysis included data obtained at baseline (BL), Visit 1 (V1; ≥1 month), Visit 2 (V2; ≥4 months) and Visit 3 (V3; ≥7 months); all available data for patients treated with aPR 30 mg twice daily were included in the analysis. A subgroup analysis was performed among patients categorized by cDAPSA disease activity scores at BL. Clinical characteristics and disease assessments at BL and V1-3 were assessed. Mean PsAID9 scores and proportions of patients meeting the PsAID Patient-Acceptable Symptom State (PASS), defined as a PsAID9 score of 4, were assessed by cDAPSA category at BL. Analyses are based on data as observed at each visit. Pearson’s correlations were calculated between cDAPSA and PsAID9 at BL, V1, V2 and V3. Results A total of 394 patients were included in the analysis population (mean age: 55.1 years; female: 55.1%; previous biologic use: 25.4%). At BL, patients had a mean PsAID9 score of 5.3 and a mean cDAPSA score of 26.6. Continuous improvements in swollen/tender joint counts and patient-reported pain and disease activity were observed with continued aPR treatment (Table). Patients reported incrementally reduced mean cDAPSA scores and consistent improvements in PsAID9 scores from BL to V3. Patients with low disease activity (cDAPSA >4 to ≤13) at BL had a mean (SD) PsAID9 score of 3.4 (1.7) with 71.1% in PsAID PASS (Figure). Those with moderate (cDAPSA >13 to ≤27) and high (cDAPSA >27) disease activity had mean (SD) PsAID9 scores of 5.3 (1.9) and 6.1 (1.8), with 26.6% and 11% showing PsAID PASS, respectively. At follow-up visits, greater proportions of patients achieving cDAPSA low disease activity or remission also achieved PsAID PASS (Figure). Significant moderate to high correlations were observed between cDAPSA and PsAID9 at BL (Pearson’s coefficient r=0.43), V1 (r=0.51; P Conclusion Results from this observational PsA study of aPR demonstrate a significant correlation between disease activity, as assessed by cDAPSA, and PsA-specific life impact/HRQoL, as measured by PsAID9. More patients met the PsAID PASS cutoff while achieving remission or lower disease activity, and improvements in PsA disease activity are associated with the PsAID PASS from a life impact perspective. Disclosure of interests Ana-Maria Orbai Grant/research support from: abbVie, Celgene, Horizon Pharma, Janssen, Lilly, and Novartis, Consultant for: Lilly, Janssen, Novartis, Pfizer, and UCB, Klaus Krueger: None declared, Frank Behrens Grant/research support from: abbVie, Pfizer, Roche, Chugai, Prophylix, Bioline, Novartis, Consultant for: abbVie, Pfizer, Roche, Chugai, UCB, Bristol-Myers Squibb, Celgene, MSD, Novartis, Biotest, Janssen, Genzyme, Eli Lilly, Speakers bureau: ad board: abbVie, Pfizer, Roche, Chugai, UCB, Bristol-Myers Squibb, Celgene, Novartis, Biotest, Janssen, Genzyme, Eli Lilly, Uta Kiltz Grant/research support from: abbVie, Chugai, Eli Lilly, Grunenthal, Janssen, MSD, Novartis, Pfizer, Roche, and UCB., Consultant for: abbVie, Chugai, Eli Lilly, Grunenthal, Janssen, MSD, Novartis, Pfizer, Roche, and UCB., Benoit Guerette Employee of: Celgene Corporation, Lillian Mellars Employee of: Celgene Corporation, Michele Brunori Employee of: Celgene Corporation, Jurgen Wollenhaupt Grant/research support from: Pfizer inc, Consultant for: Pfizer inc, Speakers bureau: Pfizer inc" @default.
• W2949273846 created "2019-06-27" @default.
• W2949273846 creator A5000055985 @default.
• W2949273846 creator A5001947020 @default.
• W2949273846 creator A5012842018 @default.
• W2949273846 creator A5035639364 @default.
• W2949273846 creator A5040852924 @default.
• W2949273846 creator A5043615700 @default.
• W2949273846 creator A5048637065 @default.
• W2949273846 creator A5056008981 @default.
• W2949273846 date "2019-06-01" @default.
• W2949273846 modified "2023-09-26" @default.
• W2949273846 title "AB0773 PSORIATIC ARTHRITIS IMPACT OF DISEASE QUESTIONNAIRE SCORES ARE CORRELATED WITH DISEASE ACTIVITY, AS MEASURED BY CDAPSA, IN PATIENTS WITH PSORIATIC ARTHRITIS" @default.
• W2949273846 doi "https://doi.org/10.1136/annrheumdis-2019-eular.1476" @default.
• W2949273846 hasPublicationYear "2019" @default.
• W2949273846 type Work @default.
• W2949273846 sameAs 2949273846 @default.
• W2949273846 citedByCount "0" @default.
• W2949273846 crossrefType "proceedings-article" @default.
• W2949273846 hasAuthorship W2949273846A5000055985 @default.
• W2949273846 hasAuthorship W2949273846A5001947020 @default.
• W2949273846 hasAuthorship W2949273846A5012842018 @default.
• W2949273846 hasAuthorship W2949273846A5035639364 @default.
• W2949273846 hasAuthorship W2949273846A5040852924 @default.
• W2949273846 hasAuthorship W2949273846A5043615700 @default.
• W2949273846 hasAuthorship W2949273846A5048637065 @default.
• W2949273846 hasAuthorship W2949273846A5056008981 @default.
• W2949273846 hasBestOaLocation W29492738461 @default.
• W2949273846 hasConcept C126322002 @default.
• W2949273846 hasConcept C159110408 @default.
• W2949273846 hasConcept C16005928 @default.
• W2949273846 hasConcept C1862650 @default.
• W2949273846 hasConcept C2776260265 @default.
• W2949273846 hasConcept C2777077863 @default.
• W2949273846 hasConcept C2779134260 @default.
• W2949273846 hasConcept C2779951463 @default.
• W2949273846 hasConcept C2780564577 @default.
• W2949273846 hasConcept C2781427535 @default.
• W2949273846 hasConcept C535046627 @default.
• W2949273846 hasConcept C61943457 @default.
• W2949273846 hasConcept C71924100 @default.
• W2949273846 hasConceptScore W2949273846C126322002 @default.
• W2949273846 hasConceptScore W2949273846C159110408 @default.
• W2949273846 hasConceptScore W2949273846C16005928 @default.
• W2949273846 hasConceptScore W2949273846C1862650 @default.
• W2949273846 hasConceptScore W2949273846C2776260265 @default.
• W2949273846 hasConceptScore W2949273846C2777077863 @default.
• W2949273846 hasConceptScore W2949273846C2779134260 @default.
• W2949273846 hasConceptScore W2949273846C2779951463 @default.
• W2949273846 hasConceptScore W2949273846C2780564577 @default.
• W2949273846 hasConceptScore W2949273846C2781427535 @default.
• W2949273846 hasConceptScore W2949273846C535046627 @default.
• W2949273846 hasConceptScore W2949273846C61943457 @default.
• W2949273846 hasConceptScore W2949273846C71924100 @default.
• W2949273846 hasLocation W29492738461 @default.
• W2949273846 hasOpenAccess W2949273846 @default.
• W2949273846 hasPrimaryLocation W29492738461 @default.
• W2949273846 hasRelatedWork W2327210964 @default.
• W2949273846 hasRelatedWork W2412283659 @default.
• W2949273846 hasRelatedWork W2412621561 @default.
• W2949273846 hasRelatedWork W2416788676 @default.
• W2949273846 hasRelatedWork W2549524683 @default.
• W2949273846 hasRelatedWork W2553111657 @default.
• W2949273846 hasRelatedWork W2756322479 @default.
• W2949273846 hasRelatedWork W2756423462 @default.
• W2949273846 hasRelatedWork W2884688806 @default.
• W2949273846 hasRelatedWork W2900774082 @default.
• W2949273846 hasRelatedWork W2949152552 @default.
• W2949273846 hasRelatedWork W2950366068 @default.
• W2949273846 hasRelatedWork W2950515735 @default.
• W2949273846 hasRelatedWork W2950611287 @default.
• W2949273846 hasRelatedWork W2966054741 @default.
• W2949273846 hasRelatedWork W3033093988 @default.
• W2949273846 hasRelatedWork W3043093053 @default.
• W2949273846 hasRelatedWork W3122627911 @default.
• W2949273846 hasRelatedWork W3164000502 @default.
• W2949273846 hasRelatedWork W3165225428 @default.
• W2949273846 isParatext "false" @default.
• W2949273846 isRetracted "false" @default.
• W2949273846 magId "2949273846" @default.
• W2949273846 workType "article" @default.